Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | BLM | P54132 | 3/20 | 0.73 |
| ▸ | HTR2A | P28223 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.73 |
| ▸ | HTR1A | P08908 | 2/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.73 |
| ▸ | HTR2C | P28335 | 2/20 | 0.73 |
| ▸ | HTR2B | P41595 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.73 |
| ▸ | HTR7 | P34969 | 1/20 | 0.73 |
| ▸ | MTOR | P42345 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307776 | 1.00 | KMT2A (0.73) | KMT2ABLMHTR2AKDM4ELMNA | |
| SCHEMBL29382361 | 1.00 | KMT2A (0.73) | KMT2ABLMHTR2AKDM4ELMNA | |
| SCHEMBL30405928 | 1.00 | KMT2A (0.73) | KMT2ABLMHTR2AKDM4ELMNA | |
| SCHEMBL5493779 | 1.00 | KMT2A (0.73) | KMT2ABLMHTR2AKDM4ELMNA | |
| SCHEMBL19871231 | 1.00 | KMT2A (0.73) | KMT2ABLMHTR2AKDM4ELMNA | |
| Tryptophan SCHEMBL7091652 | 0.94 | KMT2A (0.78) | KMT2ABLMHTR2AKDM4ELMNA | |
| D-Tryptophan SCHEMBL8103547 | 0.94 | KMT2A (0.78) | KMT2ABLMHTR2AKDM4ELMNA | |
| Tryptophan SCHEMBL7091650 | 0.94 | KMT2A (0.78) | KMT2ABLMHTR2AKDM4ELMNA | |
| D-Tryptophan SCHEMBL8103544 | 0.94 | KMT2A (0.78) | KMT2ABLMHTR2AKDM4ELMNA | |
| SCHEMBL28473836 | 0.93 | HTR2A (0.64) | KMT2ABLMHTR2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | claimed |
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | ALPHA 9 ONCOLOGY INC (CA) | 2026-03-19 | — | — | US | claimed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | claimed |
| US-12203115-B2 | Universal platform for genetic code expansion | TRUSTEES OF BOSTON COLLEGE (US) | 2025-01-21 | — | — | US | claimed |
| US-20240350681-A1 | RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2024-10-24 | — | — | US | claimed |
| CN-116371466-B | Molecularly imprinted polymer modified magnetic immobilized tryptophan catalyst and preparation method and application thereof | 西安交通大学 | 2024-06-07 | — | — | CN | claimed |
| US-11992537-B2 | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2024-05-28 | — | — | US | claimed |
| US-20240084002-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2024-03-14 | — | — | US | claimed |
| EP-4255423-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | Lankenau Institute for Medical Research (US) | 2023-10-11 | — | — | EP | claimed |
| CN-116836959-A | Enzyme composition for synthesizing neomycin derivative and application thereof | 山东大学 | 2023-10-03 | — | — | CN | claimed |
| CN-1794986-A | Novel methods for the treatment of cancer | LANKENAU INST MEDICAL RES (US) | 2006-06-28 | — | — | CN | claimed |
| EP-1613308-A1 | NOVEL METHODS FOR THE TREATMENT OF CANCER | Lankenau Institute for Medical Research (US) | 2006-01-11 | — | — | EP | claimed |
| WO-2004093871-A1 | NOVEL METHODS FOR THE TREATMENT OF CANCER | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2004-11-04 | — | — | WO | claimed |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | claimed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| EP-1219603-A2 | Tryptophan analogs in proteins, peptides and peptidic structures | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2002-07-03 | — | — | EP | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | KMT2A 1848/4885BLM 3782/4885HTR2A 3159/4885 |
| US-20240084002-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | IDO1, IDO2, TIE1 | KMT2A 2568/4885BLM 2636/4885HTR2A 3120/4885 |
| US-11992537-B2 | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy | MC1R, MC5R, MC3R | KMT2A 1625/4885BLM 3027/4885HTR2A 156/4885 |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | KMT2A 1567/4885BLM 4877/4885HTR2A 2710/4885 |
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | GRPR, GIPR, GLP1R | KMT2A 4091/4885BLM 2015/4885HTR2A 126/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | KMT2A 2188/4885BLM 4297/4885HTR2A 799/4885 |
| US-20240350681-A1 | RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY | MC1R, MC3R, MC5R | KMT2A 1737/4885BLM 3102/4885HTR2A 146/4885 |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | GLS, DBH, APEH | KMT2A 1568/4885BLM 4881/4885HTR2A 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.